research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
Elagolix did not effectively treat polycystic ovary syndrome.
Search
forResearch
5 / 1000+ results
research Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles
Adenosine helps hair grow longer and stronger by boosting certain growth factors and signaling pathways.
research Expression of Cyclooxygenase Isozymes During Morphogenesis and Cycling of Pelage Hair Follicles in Mouse Skin: Precocious Onset of the First Catagen Phase and Alopecia upon Cyclooxygenase-2 Overexpression
Overexpression of COX-2 causes early hair loss in mice, but can be prevented with a COX-2 inhibitor.
research Final Phase in the Validation of the Cross-Cultural Adaptation of the Hair-Specific Skindex-29 Questionnaire Into Spanish: Sensitivity to Change and Correlation With the 12-Item Short-Form Health Survey
The Spanish Hair-Specific Skindex-29 questionnaire effectively measures the quality of life impact of hair loss in Spanish-speaking women.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
Community Join
5 / 1000+ resultscommunity Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
community VDPHL01 phase-2/3 results comparison
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
community GT20029 Phase 2 results are out
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
community People are hyped about PP405 but what about Veradermics phase 2!
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Learn
5 / 801 resultslearn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Minoxidil
An essential vasodilator with some anti-androgenic effects, has excellent safety record
Clinics
1 / 4 results
Experts
— no results